Hematologic malignancies in the Japanese patients with inflammatory bowel disease

Norimasa Fukata, Kazuichi Okazaki, Mika Omiya, Mitsunobu Matsushita, Mamoru Watanabe, Hirohito Tsubouchi, Kozo Imai, Iwao Sasaki, Fumiaki Ueno, Yoshihide Fujiyama, Yoshio Hirota, Toshiyuki Matsui, Soichiro Miura, Toshifumi Hibi, Yutaka Kohgo, Yasuo Suzuki, Tsutomu Chiba, Yoichi Ajioka, Toshiaki Watanabe, Akira SugitaTakayuki Matsumoto, Yoshiaki Arimura, Hideki Iijima, Bun Ei Iizuka, Masahiro Iizuka, Hiroki Ikeuchi, Yoh Ishiguro, Shunji Ishihara, Hiroaki Ito, Yasushi Iwao, Hidehisa Ohi, Kiyotaka Okawa, Jun Kato, Shingo Kameoka, Yoshitaka Kinouchi, Atsuo Kitano, Fukunori Kinjo, Masato Kusunoki, Shin Ei Kudo, Kiyonori Kobayashi, Hidemi Goto, Makoto Sasaki, Masayuki Saruta, Seiji Shimizu, Takashi Joh, Kazuhito Sugimura, Kenji Suzuki, Shinji Tanaka, Taeko Dohi, Yuji Naito, Atsushi Nakajima, Katsuyoshi Hatakeyama, Ken Haruma, Ichiro Hirata, Hisao Fujii, Kitaro Futami, Yuji Funayama, Keiichi Mitsuyama, Satoshi Motoya, Kazuhiko Yoshioka, Atsushi Yoden, Kenji Watanabe, Hitoshi Asakura, Tetsuichiro Muto, Akihiro Munakata, Tatsuro Katsuno, Takashi Kagaya, Katsuyuki Fukuda, Reiko Kunisaki, Hitoshi Tajiri, Takashi Ishige, Shojiro Yamamoto

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Background Although attention has been focused for over 20 years on the possible increased risk for hematologic malignancies (HM) in patients with inflammatory bowel diseases (IBD) receiving immune-modulators or anti-TNF-alpha antibodies, the association is still controversial. To understand the actual conditions of HM in the Japanese patients with IBD, the research committee for IBD supported by the Ministry of Health, Welfare and Labor of Japan (IBD-MHWL) conducted a multi-center retrospective study. Methods Questionnaires for the development of HM in IBD patients were sent to the 70 facilities participating with IBD-MHWL in the first survey, followed by the second survey using a more detailed questionnaire, sent to the 27 members with HM patients. Results Out of a total of 36,939 IBD patients in 70 facilities, 28 cases of HM related with IBD [12 of 10,500 UC patients (0.11 %), 16 of 6,310 CD patients (0.25 %)] were analyzed. The numbers of UC patients who developed HM were 2 (0.15 %) from the group receiving and 10 (0.13 %) from the group non-receiving thiopurine, without significant differences. The numbers of CD patients who developed HM were 4 (0.39 %) from the group receiving and 12 (0.21 %) from the group non-receiving thiopurine, without significant differences. The odds ratios of developing HM by thiopurine were 1.37 (95 % CI 0.30–6.24) in UC patients and 1.86 (95 % CI 0.60–5.78) in CD patients. Conclusions Our results suggested that thiopurine therapy may not be a risk factor for HM in Japanese patients with IBD. Further accumulation of cases and prospective studies are necessary to conclude this important issue.

Original languageEnglish
Pages (from-to)1299-1306
Number of pages8
JournalJournal of gastroenterology
Volume49
Issue number9
DOIs
Publication statusPublished - 2014 Sep

Keywords

  • Crohn’s disease
  • Hematologic malignancy
  • Inflammatory bowel disease
  • Lymphoproliferative disorder
  • Thiopurine
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Hematologic malignancies in the Japanese patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this